All > Nasopharyngeal Carcinoma

P-MUC1C-ALLO1 CAR-T cells for Colorectal Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
MD Anderson Cancer Center, Houston, TXColorectal Cancer+8 MoreP-MUC1C-ALLO1 CAR-T cells - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment in adults with advanced or metastatic epithelial-derived solid tumors.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pancreatic Cancer
  • Breast Cancer
  • Nasopharyngeal Cancer
  • Stomach Cancer
  • Ovarian Cancer
  • Kidney Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
DD HST-NEETs
1
huMNC2-CAR44 CAR T cells
1
HER2 Specific CAR T Cell

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Baseline through 15 years

Baseline through 15 years
Phosphorus
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
Baseline through Day 28
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
DD HST-NEETs
1
huMNC2-CAR44 CAR T cells
1
HER2 Specific CAR T Cell

Trial Design

4 Treatment Groups

P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)
1 of 4
P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)
1 of 4
P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
1 of 4
P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)
1 of 4

Experimental Treatment

100 Total Participants · 4 Treatment Groups

Primary Treatment: P-MUC1C-ALLO1 CAR-T cells · No Placebo Group · Phase 1

P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)Experimental Group · 2 Interventions: Rimiducid, P-MUC1C-ALLO1 CAR-T cells · Intervention Types: Drug, Biological
P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)Experimental Group · 2 Interventions: Rimiducid, P-MUC1C-ALLO1 CAR-T cells · Intervention Types: Drug, Biological
P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)Experimental Group · 2 Interventions: Rimiducid, P-MUC1C-ALLO1 CAR-T cells · Intervention Types: Drug, Biological
P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)Experimental Group · 2 Interventions: Rimiducid, P-MUC1C-ALLO1 CAR-T cells · Intervention Types: Drug, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rimiducid
2019
Completed Phase 1
~20

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline through 15 years

Who is running the clinical trial?

Poseida Therapeutics, Inc.Lead Sponsor
4 Previous Clinical Trials
305 Total Patients Enrolled
Rajesh Belani, M.D.Study DirectorSponsor Executive Medical Director
4 Previous Clinical Trials
305 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have been diagnosed with advanced cancer that cannot be removed through surgery and has not responded to standard treatments or you are not eligible or have refused other available treatment options.
You must have tissue samples of your tumor stored, or agree to have a new sample collected.
You agree to use birth control during the study.
You need to have fully recovered from any side effects caused by previous treatments.
References

Frequently Asked Questions

How many volunteers have registered for this medical experiment?

"Poseida Therapeutics, Inc., the entity responsible for this research project, must identify 100 individuals that meet the protocol's eligibility requirements. The trial will be conducted in multiple sites including MD Anderson Cancer Center (Houston, Texas) and University of California, San Francisco (San Francisco, California)." - Anonymous Online Contributor

Unverified Answer

Are there any openings for this research endeavor at the present?

"According to clinicaltrials.gov, this medical trial is actively recruiting participants at the time of writing. The initial posting was on February 15th 2022 and it has been adjusted lastly on October 26th 2022." - Anonymous Online Contributor

Unverified Answer

What regulatory approval has P-MUC1C-ALLO1 CAR-T cells obtained?

"Due to the limited amount of data corroborating its efficacy and safety, P-MUC1C-ALLO1 CAR-T cells has been ranked a 1 on our team's scale." - Anonymous Online Contributor

Unverified Answer

What is the geographic distribution of this experiment?

"This medical study has opened enrolment at 5 distinct locations, including MD Anderson Cancer Center in Houston and NEXT Oncology in San Antonio. Additionally, there are 3 other sites participating such as University of California – San Francisco." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top